Lupin Ltd
Company Profile
Business description
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
Contact
Off. Western Express Highway
3rd floor, Kalpataru Inspire
Santacruz (East)
MumbaiMH400055
INDT: +91 2266402323
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
19,862
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,629.10 | 51.40 | -0.59% |
CAC 40 | 7,892.61 | 55.21 | 0.70% |
DAX 40 | 21,411.53 | 157.26 | 0.74% |
Dow JONES (US) | 44,438.60 | 281.87 | 0.64% |
FTSE 100 | 8,565.20 | 20.07 | 0.23% |
HKSE | 19,700.56 | 78.21 | -0.40% |
NASDAQ | 19,929.27 | 80.07 | -0.40% |
Nikkei 225 | 39,958.87 | 312.62 | 0.79% |
NZX 50 Index | 13,060.08 | 22.94 | 0.18% |
S&P 500 | 6,091.91 | 5.54 | 0.09% |
S&P/ASX 200 | 8,378.70 | 51.10 | -0.61% |
SSE Composite Index | 3,230.16 | 16.54 | 0.51% |